Skip to main content
AAPL $250.12 +1.24% MSFT $395.55 -0.93% GOOGL $302.28 -1.35% AMZN $207.67 +0.47% NVDA $180.25 +1.43% TSLA $391.20 -0.83% META $613.71 -1.32% JPM $283.44 -1.32% V $307.14 +0.00% WMT $126.52 +0.95% AAPL $250.12 +1.24% MSFT $395.55 -0.93% GOOGL $302.28 -1.35% AMZN $207.67 +0.47% NVDA $180.25 +1.43% TSLA $391.20 -0.83% META $613.71 -1.32% JPM $283.44 -1.32% V $307.14 +0.00% WMT $126.52 +0.95%

NASDAQ: KLRS

Kalaris Therapeutics Inc

Healthcare • Biotechnology • www.kalaristx.com

$8.67 $-0.50 (-5.45%)

Data as of Mar 14, 2:01 PM UTC

3.8
SID Score

Key Statistics

Market Cap $157.29M
P/E Ratio -3.04
Dividend Yield 0.00%
Volume 32,467
Avg Volume 175,853
52-Week High $10.19
52-Week Low $8.55

About Kalaris Therapeutics Inc

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Analyst Ratings

View All →
N/A Based on 0 analysts
Avg Price Target $3.00 (-65.4% upside)

KLRS News

View All →

KLRS FAQ

What is Kalaris Therapeutics Inc's stock price today?

Kalaris Therapeutics Inc (NASDAQ:KLRS) stock is trading at $8.67 as of the latest market data.

FEATURED BY